BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.78 0.11 (1.43%) Market Cap: 1.61 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 78/100

Q1 2022 BioCryst Pharmaceuticals Inc Earnings Call Transcript

May 05, 2022 / 12:30PM GMT
Release Date Price: $9.78 (-3.93%)
Operator

Good day, and thank you for standing by. Welcome to the BioCryst Pharmaceuticals First Quarter 2022 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, John Bluth, Head of Investor Relations at BioCryst.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - Chief Communications Officer

Thanks, Daniel. Good morning, and welcome to BioCryst's First Quarter 2022 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website.

Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; Chief Medical Officer, Dr. Bill Sheridan; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we will answer your questions.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot